利伐沙班与低分子肝素对髋膝关节置换术后下肢深静脉血栓预防的应用评价
Effect comparison between rivaroxaban and low molecular weight heparin in the prevention of deep venous thrombosis after hip and knee joint arthroplasty
-
摘要: 目的：通过对髋膝关节置换术术后病人分别使用利伐沙班和注射用低分子量肝素钙，来评价2种药物的临床疗效，进一步探讨临床药师在髋膝关节置换术术后的预防中，如何协助临床医生使用抗凝药物进行治疗。方法：收集100例髋、膝关节置换术的病人，随机分为利伐沙班组50例和低分子肝素组50例。利伐沙班组病人于术后8 h给予利伐沙班片10 mg，每天1次，口服；低分子肝素组病人于术后12 h给予低分子量肝素5 000抗Xa国际单位，每天1次，皮下注射。2组均连续治疗2周。观察比较2组病人的凝血指标血小板（PLT）、活化部分凝血活酶（APTT）、凝血酶原时间（PT）及下肢深静脉血栓（DVT）发生率。临床药师参与治疗过程并提供药学监护。结果：2组病人术前血小板及凝血指标均无异常，且2组间差异无统计学意义（P>0.05）。2组病人术后药物治疗前及治疗后14 d血小板及凝血指标均无异常，且2组间差异无统计学意义（P>0.05）。2组病人中利伐沙班组深静脉血栓形成（DVT）发生率为0%（0/50），低分子肝素组DVT发生率为8%（4/50），2组差异有统计学意义（P<0.05）。2组病人中利伐沙班组不良反应发生率为2%（1/50），低分子肝素组为12%（6/50），差异无统计学意义（P>0.05）。结论：利伐沙班能有效预防髋膝关节置换术后下肢深静脉血栓的发生，不增加出血风险，具有良好的安全性，其疗效与低分子肝素相当。且利伐沙班具备可口服、固定剂量、疗效满意、无需监测等优点。Abstract: Objective:To compare the clinical efficacy between rivaroxaban and low molecular weight heparin calcium injection in the prevention of deep venous thrombosis after hip and knee joint arthroplasty,and guide clinical rational use of anticoagulant.Methods:One hundred patients with hip and knee arthroplasty were randomly divided into the rivaroxaban group and low molecular weight heparin group(50 cases each group).The rivaroxaban group was treated with 10 mg of rivaroxaban once daily by oral after 8 hours of operation,and the low molecular weight heparin group was treated with 5 000 AXaIU of low molecular weight heparin once daily by subcutaneous injection after 12 hours of operation.Two groups were continuously treated for 2 weeks.The blood coagulation indexes[including platelet,activated partial thromboplastin,prothrombin time and incidence rate of lower extremity deep venous thrombosis(DVT)] were compared between two groups.Clinical pharmacists participated in the treatment process,and provided pharmaceutical care.Results:The platelet counts and coagulation parameters in two groups were normal before surgery,and the difference of which was not statistically significant between two groups(P>0.05).The platelet counts and coagulation parameters in the two groups were normal before treatment and after 14 days of treatment,and the difference of which was not statistically significant between in two groups(P>0.05).The incidence rates of DVT in rivaroxaban group and low molecular weight heparin group were 0%(0/50) and 8%(4/50),respectively,and the difference of which was statistically significant between the two groups(P<0.05).The incidence rates of adverse reactions in rivaroxaban group and low molecular weight heparin group were 2%(1/50) and 12%(6/50),respectively,and the difference of which was not statistically significant between the two groups(P>0.05).Conclusions:Rivaroxaban can effectively prevent the occurrence of thrombosis in lower extremities deep vein after hip and knee joint arthroplasty,does not increase the risk of bleeding and has good safety,and the curative effect of which is equivalent to low molecular weight heparin.Rivaroxaban has the advantages of oral administration,fixed dose,satisfactory efficacy,and need not monitor.
-
[1] 查振刚,臧学慧,姚平,等.全髋关节置换术后深静脉血栓形成的临床研究及危险因素分析[J].中华骨科杂志,2005,43(8):512. [2] 陈丽珊,施楚君,张志坚,等.系统机械性疗法与化学性疗法预防髋关节置换患者下肢深静血栓形成的效果对照[J].中国组织工程研究与临床康复,2007,11(27):5435. [3] 彭慧明,翁习生,翟吉良,等.初次全膝关节成形术后常规抗凝患者症状性静脉血栓症发生率的调查研究[J].中国骨与关节外科,2014,7(2):101. [4] 尹向辉,张庆恩,张雪松,等.下肢血液循环泵联合利伐沙班预防下肢关节置换术后静脉血栓形成临床研究[J].中国药业,2014,23(23):12. [5] 史旭波.新型口服抗凝药预防骨科大手术后深静脉血栓栓塞症的研究进展[J].中华关节外科杂志,2014,8(6):813. [6] 王月,王铁铸,吕志伟,等.老年髋部骨折术后下肢深静脉血栓形成的预防[J].中国骨与关节损伤杂志,2013,28(2):137. [7] 中华医学会骨科学分会.中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志,2016,36(20):65. [8] 陈露.彩色多普勒超声在下肢深静脉血栓诊断中的应用价值[J].蚌埠医学院学报,2015,40(7):959. [9] 张征,苏里亚,徐光,等.彩色多普勒超声对围手术期盆腔肿瘤患者下肢静脉血流评估的意义[J].蚌埠医学院学报,2014,39(4):528. [10] XU Z,DAI X,YAO Y,et al.Higher levels of serum triglycerides were associated with postoperative deep vein thrombosis after total hip arthroplasty in patients with nontraumatic osteonecrosis of the femoral head[J].Int J Low Extrem Wounds,2015,30(12):2042. [11] 胡云芝,倪红霞,韩梅.低分子肝素钙两种皮下注射法比较[J].蚌埠医学院学报,2010,35(3):297. [12] 周筠,毕方刚,陈聚伍,等.利伐沙班与低分子肝素对骨折患者下肢深静脉血栓预防的疗效比较[J].中华实验外科杂志,2015,32(12):3187. [13] 袁国伟,王步云,巫水周,等.低分子肝素对老年髋部骨折患者术前下肢深静脉血栓及D-二聚体水平的影响[J].中国老年学杂志,2014,10(13):3617. [14] 胡卫国,袁耀.利伐沙班用于髋、膝关节置换术后抗凝效果的临床观察[J].中国基层医药,2016,23(15):2328. [15] RUSSELL RD,HOTCHKISS WR,KNIGHT JR,et al.The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty[J].Thrombosis,2013,2013:762310. [16] 周健,刘忠达,林伟龙.髋关节置换术后利伐沙班预防下肢深静脉血栓的疗效与安全性[J].中国临床药理学杂志,2015,31(2):1106. [17] 武通.利伐沙班与低分子肝素预防髋关节置换术后深静脉血栓形成的疗效对比[J].北方药学,2017,14(5):121. [18] 苏嘉,戴寿旺,郭晓山.利伐沙班预防胸腰椎骨折术后深静脉血栓形成的有效性及安全性研究[J].浙江创伤外科,2013,20(3):522. [19] SCHILLIG J,KAATZ S,HUDSON M,et al.Clinical and safety impact of an inpatient pharmacist directed anticoagulation service[J].J Hosp Med,2011,6(6):322. -
点击查看大图
计量
- 文章访问数: 4814
- HTML全文浏览量: 645
- PDF下载量: 14
- 被引次数: 0
下载:
